Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SR122
- Lead developer
- Suzhou Ribo Life Science
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SR122 is an investigational dual-targeting small interfering RNA (siRNA) therapeutic conjugated to GalNAc (N-acetylgalactosamine) for liver-targeted delivery. Developed by Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals, SR122 simultaneously silences apolipoprotein C-III (ApoC3) and proprotein convertase subtilisin/kexin type 9 (PCSK9), two clinically validated pathways involved in lipid metabolism. By targeting both triglyceride-rich lipoproteins and low-density lipoprotein cholesterol (LDL-C), the drug is designed to treat dyslipidemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidemia. SR122 is administered via subcutaneous injection.
02
Targets
Beyond the preview
Go deeper on SR122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SR122.
Work on SR122? Claim this page to correct or add information. Claim this page